SCHEMBL10242020

SCHEMBL10242020

Cc1cc(-c2cn3ccccc3n2)ccc1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.76
GFER P55789 4/20 0.76
KMT2A Q03164 3/20 0.76
GAA P10253 2/20 0.76
MEN1 O00255 1/20 0.76
MIF P14174 1/20 0.76
CLK1 P49759 1/20 0.64
DYRK1A Q13627 1/20 0.64
NPC1 O15118 10/20 0.62
KDM4E B2RXH2 8/20 0.62
PKM P14618 5/20 0.58
ALDH1A1 P00352 4/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
MAPK1 P28482 3/20 0.58
HPGD P15428 2/20 0.58
TP53 P04637 1/20 0.58
TSHR P16473 1/20 0.58
HSD17B10 Q99714 1/20 0.58
POLB P06746 3/20 0.56
EPHX2 P34913 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8340215 0.89 RAB9A (0.76) RAB9AGFERKMT2AGAAMEN1
SCHEMBL4728739 0.87 RAB9A (1.00) RAB9AGFERKMT2AGAAMEN1
SCHEMBL6875395 0.87 RAB9A (0.64) RAB9AGFERKMT2AGAAMEN1
Hydrochloric Acid SCHEMBL6392312 0.85 RAB9A (0.62) RAB9AGFERKMT2AGAAMEN1
SCHEMBL12848509 0.82 RAB9A (0.76) RAB9AGFERKMT2AGAAMEN1
SCHEMBL18026525 0.81 NPC1 (0.57) RAB9AGFERKMT2AGAAMEN1
Bromide SCHEMBL6525392 0.81 RAB9A (0.79) RAB9AGFERKMT2AGAAMEN1
SCHEMBL5305222 0.81 RAB9A (0.61) RAB9AGFERKMT2AGAAMEN1
SCHEMBL7685361 0.80 RAB9A (0.67) RAB9AKMT2AGAAMEN1NPC1
SCHEMBL13325909 0.79 RAB9A (0.83) RAB9AGFERKMT2AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895599-B2 Lipoprotein lipase-activating compositions comprising benzene derivates OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2014-11-25 US disclosed
US-20130296342-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2013-11-07 US disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-20110065728-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2011-03-17 US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 US disclosed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 US disclosed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 US disclosed
US-20080318956-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-12-25 US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US disclosed
EP-1847263-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-24 EP disclosed
EP-1844766-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-17 EP disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296342-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES LPL, LIPC, LIPE RAB9A 3933/4885GFER 1731/4885KMT2A 1472/4885
US-20110065728-A1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES LPL, LIPC, LIPE RAB9A 3849/4885GFER 1844/4885KMT2A 1669/4885
US-20080090779-A1 ANTIALLERGIC AGENTS NAT1, EPX, HRH2 RAB9A 2827/4885GFER 1665/4885KMT2A 302/4885
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A RAB9A 997/4885GFER 3421/4885KMT2A 4486/4885
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A RAB9A 1124/4885GFER 3396/4885KMT2A 4531/4885
US-20080318956-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A RAB9A 1124/4885GFER 3396/4885KMT2A 4531/4885
US-20070185110-A1 Antiallergic agents NAT1, EPX, AHR RAB9A 2704/4885GFER 1509/4885KMT2A 199/4885
US-20070185059-A1 Antiallergic agents NAT1, EPX, AHR RAB9A 2770/4885GFER 1579/4885KMT2A 210/4885
US-20070042997-A1 Medicament for treatment of dermal pigmentation TYR, XDH, XPA RAB9A 3815/4885GFER 2180/4885KMT2A 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.